Shanghai Bao Pharmaceuticals Co., Ltd. (HKG:2659)

Market Cap	3.04B
Revenue (ttm)	19.67M -63.5%
Net Income	-422.41M
EPS	-1.37
Shares Out	323.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,314,800
Open	9.58
Previous Close	9.18
Day's Range	9.01 - 10.08
52-Week Range	6.48 - 206.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About HKG:2659

Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 364
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2659

Financial Performance

In 2025, HKG:2659's revenue was 49.16 million, an increase of 697.99% compared to the previous year's 6.16 million. Losses were -395.30 million, 8.47% more than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 11, 2026

Data Sources Report a data error